Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Rice University researchers set stage for large-scale synthesis of cytotoxic agent to treat cancer

Rice University researchers set stage for large-scale synthesis of cytotoxic agent to treat cancer

Studies explore possible link between pediatric cancer and light therapy for newborn jaundice

Studies explore possible link between pediatric cancer and light therapy for newborn jaundice

Researchers identify potential ways in which cancer cells may develop resistance to BET inhibitors

Researchers identify potential ways in which cancer cells may develop resistance to BET inhibitors

AKR1C3 enzyme could be promising therapeutic target for managing CRPC, AML

AKR1C3 enzyme could be promising therapeutic target for managing CRPC, AML

Penn State researchers link mutation in common virus to fatal brain disease

Penn State researchers link mutation in common virus to fatal brain disease

Neurotoxic effects of chemotherapy may impair cognitive function in young ALL patients

Neurotoxic effects of chemotherapy may impair cognitive function in young ALL patients

New bio-mimicry method allows scientists to track cells in vivo using MRI during preclinical, clinical trials

New bio-mimicry method allows scientists to track cells in vivo using MRI during preclinical, clinical trials

Novel therapeutic approach to treat leukaemia patients

Novel therapeutic approach to treat leukaemia patients

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

Arkin Holdings and Primera Capital lead investment of $13M in BioSight

Arkin Holdings and Primera Capital lead investment of $13M in BioSight

CTD helps scientists explore impact of environmental exposures on human health

CTD helps scientists explore impact of environmental exposures on human health

Mitoxantrone drug users more likely to develop colorectal cancer

Mitoxantrone drug users more likely to develop colorectal cancer

Researchers discover new function of genes in Fanconi anemia pathway

Researchers discover new function of genes in Fanconi anemia pathway

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

Residential radon exposure may lead to hematologic cancer risk in women

Residential radon exposure may lead to hematologic cancer risk in women

Experimental therapy has over 90% remission rate for advanced leukemia patients

Experimental therapy has over 90% remission rate for advanced leukemia patients

Musashi-2 protein regulates function, development of blood stem cells

Musashi-2 protein regulates function, development of blood stem cells

Study identifies risk factors for asparaginase-induced pancreatitis in ALL patients

Study identifies risk factors for asparaginase-induced pancreatitis in ALL patients

High doses of commonly-used chemotherapy drug may increase survival rate of ALL patients

High doses of commonly-used chemotherapy drug may increase survival rate of ALL patients

BCR-ABL halving time indicates CML prognosis during front-line TKI

BCR-ABL halving time indicates CML prognosis during front-line TKI

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.